Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Today, Chardan Capital reiterated its Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY).
Some recent analyst ratings include
- 1/19/2018-Chardan Capital Reiterated Rating of Buy.
- 1/7/2018-Piper Jaffray Companies Reiterated Rating of Buy.
- 1/8/2018-B. Riley Reiterated Rating of Buy .
- 12/15/2017-Goldman Sachs Group Upgrade from a “Buy ” rating to a ” Conviction-Buy” rating.
- 11/9/2017-Cowen Reiterated Rating of Buy.
- 11/9/2017-JPMorgan Chase & Co. Upgrade from a “Neutral ” rating to a ” Overweight” rating.
Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 88.39%.
- On 1/4/2018 Michael Mason, VP, sold 36,745 with an average share price of $131.59 per share and the total transaction amounting to $4,835,274.55.
- On 12/20/2017 Laurie Keating, SVP, sold 6,249 with an average share price of $121.20 per share and the total transaction amounting to $757,378.80.
- On 12/1/2017 Laurie Keating, SVP, sold 30,000 with an average share price of $135.89 per share and the total transaction amounting to $4,076,700.00.
- On 11/22/2017 John Maraganore, CEO, sold 73,415 with an average share price of $130.90 per share and the total transaction amounting to $9,610,023.50.
- On 11/15/2017 John Maraganore, CEO, sold 74,000 with an average share price of $126.86 per share and the total transaction amounting to $9,387,640.00.
- On 11/2/2017 Dennis A Ausiello, Director, sold 20,000 with an average share price of $130.00 per share and the total transaction amounting to $2,600,000.00.
- On 10/30/2017 Akshay Vaishnaw, EVP, sold 33,666 with an average share price of $121.46 per share and the total transaction amounting to $4,089,072.36.
Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals closed the previous trading session at 124.02 up +0.03 0.02% with 124.75 shares trading hands.